A comprehensive view of Takeda Pharmaceutical Co. Ltd.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA approves subcutaneous administration of Takeda’s ENTYVIO (vedolizumab) for maintenance therapy in moderately to severely active Crohn’s Disease
Published: April 19, 2024 by Business Wire
Leaders from Genentech, Bayer, Novo Nordisk, Takeda and others to be keynote speakers at Veeva Commercial Summit; speakers to discuss strategies for effective commercialization and customer engagement
Published: April 17, 2024 by PR Newswire
Takeda is closing production at its gene therapy plant in Orth, Austria, resulting in nearly 200 job losses; despite attempts to sell the adeno-associated virus gene therapy facility, the Japan-based firm was unable to find a buyer
Published: March 13, 2024 by FiercePharma
Takeda's HYQVIA approved by FDA as maintenance therapy for adult chronic inflammatory demyelinating polyneuropathy patient; the therapy can be infused up to once per month and can be administered by healthcare professionals or self-administered
Published: January 23, 2024 by Contify Life Science News
Takeda selects Biologics by McKesson as specialty pharmacy provider for FDA-approved oral targeted therapy Fruzaqla for adults with metastatic colorectal cancer; the treatment is the first targeted therapy for the condition in over a decade
Published: November 15, 2023 by McKesson Corp.

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count